- Home
- MERC vs VTGN Comparison
MERC vs VTGN Comparison
Compare MERC & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | VTGN |
|---|---|---|
| Founded | 1968 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 122.1M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | MERC | VTGN |
|---|---|---|
| Price | $2.09 | $4.55 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 570.2K | ★ 923.0K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,906,971,000.00 | $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | $13.78 | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.48 | $1.90 |
| 52 Week High | $8.28 | $5.14 |
Technical Indicators
Market Signals| Indicator | MERC | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 55.15 |
| Support Level | $1.78 | $3.36 |
| Resistance Level | $1.95 | $4.60 |
| Average True Range (ATR) | 0.12 | 0.44 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 89.55 | 65.73 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.